Ticagrelor is a selective and reversible P2Y12 adenosine diphosphate (ADP) receptor antagonist. By binding to the platelet P2Y12 receptor, it inhibits ADP-mediated platelet activation and aggregation. Unlike thienopyridines, ticagrelor does not require metabolic activation and does not bind irreversibly to the receptor, resulting in a more rapid onset and offset of action.

Through effective inhibition of platelet aggregation, Tigel 90 mg reduces thrombus formation in patients with a high risk of ischemic cardiovascular events, thereby improving clinical outcomes following acute coronary syndromes.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Tigel Tablet 90 mg is indicated for:

• Prevention of atherothrombotic events in adults with acute coronary syndromes

• Patients with unstable angina, NSTEMI, or STEMI

• Patients managed medically or undergoing PCI or CABG

Dosage and Administration

• Treatment should be initiated with a loading dose of 180 mg (two tablets of 90 mg)

• Followed by 90 mg twice daily as maintenance therapy

• Tigel 90 mg should be taken together with aspirin

  • Initial aspirin dose: usually 325 mg

  • Maintenance aspirin dose: 75–100 mg daily

• Maintenance doses of aspirin above 100 mg should be avoided, as they reduce the effectiveness of ticagrelor

• Tablets may be taken with or without food

• Recommended duration of therapy is up to 12 months, unless clinically indicated otherwise

Drug Interactions

• Avoid strong CYP3A4 inhibitors such as ketoconazole, clarithromycin, ritonavir, and nefazodone

• Avoid strong CYP3A4 inducers including rifampicin, phenytoin, carbamazepine, and phenobarbital

• Avoid simvastatin and lovastatin doses above 40 mg

• Monitor digoxin levels when co-administered

• Compatible with heparin, beta-blockers, ACE inhibitors, ARBs, and proton pump inhibitors

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Contraindications

• Hypersensitivity to ticagrelor or any excipients

• Active pathological bleeding

• History of intracranial hemorrhage

• Moderate to severe hepatic impairment

• Concomitant use with strong CYP3A4 inhibitors

Side Effects

Common side effects include:

• Dyspnea

• Bleeding

• Headache

• Dizziness

• Nausea and diarrhea

• Hypertension and hypotension

Pregnancy and Lactation

• Pregnancy: Category C; not recommended unless clearly necessary

• Lactation: Excreted in animal milk; breastfeeding should be discontinued or therapy avoided

Precautions and Warnings

• Increased risk of bleeding

• Avoid abrupt discontinuation due to increased risk of thrombotic events

• Use with caution in hepatic impairment

Storage Conditions

Store below 25°C, protected from light and moisture. Keep out of reach of children.